Fig. 6

PARP suppression diminishes conformational activation of LFA-1 (integrin β2) in monocytes. Monocytes were treated with PARPi (olaparib, EB37, or talazoparib) or RhoA and Rac1 GTPase inhibitor (CT04 or NSC23766). Expression of total LFA-1 (CD18) was not affected by treatment with PARPi. The activated form of LFA-1 was detected using MEM-148, a conformation-specific antibody. PMA-stimulation of monocytes changes integrin conformation from a closed (inactive) to an open (active) form (a). The total amount of integrin β2 (CD18) is shown on the x-axis. b Quantitation of integrin β2 conformational activation, expressed as the percent of monocytes containing the activated integrin conformation (as shown in the right upper quadrant of each graph in panel a). Results are presented as the mean ± SEM (*P < 0.5, **P < 0.05 vs. untreated control) from three independent experiments